Nanoformulation and Preclinical Evaluation of Dihydroartemisinin–Lumefantrine and Primaquine as Combined Antimalarial Therapy

Nanoformulation and Preclinical Evaluation of Dihydroartemisinin–Lumefantrine and Primaquine as Combined Antimalarial Therapy

The World Health Organization recommends artemisinin-based combinations for uncomplicated malaria treatment. Artemether and lumefantrine (LUM) are the first-line treatments, with artemether serving as a prodrug of dihydroartemisinin (DHA), while primaquine (PQ) is primarily used as a prophylactic dr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pesila Odera, Geoffrey Otieno, Joab Onyango, Bernhards Ogutu, James Owour, Florence Oloo, Martin Ongas, Hulda Swai, Jeremiah Gathirwa
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Journal of Nanotechnology
Online Access:	http://dx.doi.org/10.1155/jnt/5162847
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
by: Robert J Commons, et al.
Published: (2019-10-01)

Antimalarial Drug Repurposing of Epirubicin and Pelitinib in Combination with Artemether and Lumefantrine
by: Douglas O. Ochora, et al.
Published: (2025-06-01)

Efficacy of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Mozambique, 2022
by: Abel Nhama, et al.
Published: (2025-07-01)

In Vivo Antimalarial Activity of Cyperus rotundus and Its Combination with Dihydroartemisinin against Plasmodium berghei
by: Sakaewan Ounjaijean, et al.
Published: (2024-01-01)

The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data.
by: WorldWide Antimalarial Resistance Network (WWARN) DP Study Group
Published: (2013-12-01)

Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
by: Bontu Abate, et al.
Published: (2025-03-01)

Detection of Falsified Antimalarial Sulfadoxine-Pyrimethamine and Dihydroartemisinin-Piperaquine Drugs Using a Low-Cost Handheld Near-Infrared Spectrometer
by: Moussa Yabré, et al.
Published: (2022-01-01)

Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials
by: Alphonse Ouédraogo, et al.
Published: (2024-12-01)

Methylene blue inhibits lumefantrine-resistant Plasmodium berghei
by: Victor Irungu Mwangi, et al.
Published: (2016-06-01)

Phytomedicine nanoformulations for Parkinson's disease
by: Chinthu V. Saji, et al.
Published: (2025-02-01)

Topic Nanoformulations with Potential Cosmetic Applications
by: Anda Maria Baroi, et al.
Published: (2023-12-01)

Erratum to: Nematicidal Properties of Chitosan Nanoformulation
by: Mouniga R., et al.
Published: (2025-06-01)

Study of nanoformulations for breast cancer treatment
by: Tang Xiaotong
Published: (2025-01-01)

Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations.
by: Yoel Lubell, et al.
Published: (2014-08-01)

Dihydroartemisinin enhances remyelination by switching microglia to the reparative phenotype
by: Li Liu, et al.
Published: (2025-08-01)

Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure.
by: Leah Mwai, et al.
Published: (2012-01-01)

Possible treatment failure of artemether-lumefantrine in an Italian traveler with uncomplicated falciparum malaria.
by: Claudio Giacomazzi, et al.
Published: (2011-01-01)

Possible treatment failure of artemether-lumefantrine in an Italian traveler with uncomplicated falciparum malaria.
by: Ernestina Carla Repetto, et al.
Published: (2011-10-01)

Nanoformulation innovations: Revolutionizing precision in migraine therapy
by: Mohammad Ghasemi Farimani, et al.
Published: (2025-01-01)

Nanoformulations of Cosmetic Interest for the Cutaneous Uptake of Nickel
by: Roberta Cassano, et al.
Published: (2025-03-01)

Tumor microenvironment–responsive nanoformulations for breast cancer
by: Pallavi Velapure, et al.
Published: (2024-12-01)

Anticancer Effects of Dihydroartemisinin on Human Esophageal Cancer Cells In Vivo
by: Cailing Jiang, et al.
Published: (2018-01-01)

Dihydroartemisinin Modulates Enteric Glial Cell Heterogeneity to Alleviate Colitis
by: Peishan Qiu, et al.
Published: (2024-09-01)

Lipid-Based Nanoformulations of [6]-Gingerol for the Chemoprevention of Benzo[a] Pyrene-Induced Lung Carcinogenesis: Preclinical Evidence
by: Faris Alrumaihi, et al.
Published: (2025-04-01)

Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients
by: Solomon M Abay, et al.
Published: (2013-06-01)

Recent advancement of fisetin-based nanoformulations in the management of psoriasis
by: Umesh B. Telrandhe, et al.
Published: (2025-07-01)

Subacute Toxicity Profile of Lacidipine Nanoformulation in Wistar Rats
by: Rupesh Shirodkar, et al.
Published: (2015-01-01)

Nanoformulations for Hydrazones; Synthesis, Characterization, Parasitology, and Histopathology Investigations
by: Eman M. Hassan, et al.
Published: (2025-05-01)

Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective
by: Mubashar Rehman, et al.
Published: (2024-10-01)

Nanoformulation: An efficient approach to natural insect repellent formulations
by: Mehrin Najafzadeh Nansa, et al.
Published: (2024-08-01)

Dihydroartemisinin inhibits lung cancer bone metastasis by modulating macrophage polarization
by: Guihua Hang, et al.
Published: (2025-04-01)

Simultaneous Estimation of Artemether and Lumefantrine by RP-HPLC Method Development in Pharmaceutical Tablet Dosage Form
by: Lekhana A M, et al.
Published: (2025-01-01)

Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia.
by: Samuel Dunyo, et al.
Published: (2011-01-01)

Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
by: Walter R J Taylor, et al.
Published: (2023-09-01)

Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
by: Walter R J Taylor, et al.
Published: (2021-09-01)

Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance.
by: Richard J Maude, et al.
Published: (2012-01-01)

Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region
by: Paula Calderón-Ruiz, et al.
Published: (2024-11-01)

Advanced Nanoformulations for Detection and Removal of Poly- and Perfluoroalkyl Substances (PFAS)
by: Jyotish Kumar, et al.
Published: (2025-04-01)

Mitigating oxidative stress toxicities of environmental pollutants by antioxidant nanoformulations
by: Hamieh Goshtasbi, et al.
Published: (2025-12-01)

Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia
by: Fanny Arcelia, et al.
Published: (2023-05-01)